Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Revenue (2020 - 2025)

Historic Revenue for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $41.6 million.

  • Maravai Lifesciences Holdings' Revenue fell 3968.85% to $41.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.4 million, marking a year-over-year decrease of 3047.06%. This contributed to the annual value of $259.2 million for FY2024, which is 1029.95% down from last year.
  • Latest data reveals that Maravai Lifesciences Holdings reported Revenue of $41.6 million as of Q3 2025, which was down 3968.85% from $47.4 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Revenue registered a high of $244.3 million during Q1 2022, and its lowest value of $41.6 million during Q3 2025.
  • Moreover, its 5-year median value for Revenue was $74.1 million (2023), whereas its average is $124.5 million.
  • In the last 5 years, Maravai Lifesciences Holdings' Revenue soared by 36428.95% in 2021 and then tumbled by 7160.9% in 2023.
  • Maravai Lifesciences Holdings' Revenue (Quarter) stood at $228.4 million in 2021, then dropped by 10.39% to $204.7 million in 2022, then tumbled by 63.78% to $74.1 million in 2023, then decreased by 23.72% to $56.6 million in 2024, then dropped by 26.39% to $41.6 million in 2025.
  • Its last three reported values are $41.6 million in Q3 2025, $47.4 million for Q2 2025, and $46.8 million during Q1 2025.